Volltext verfügbar nach Anmeldung bzw. im Campus-Netz.
3SBio to Develop DJ5 for Progressive Renal Failure in ADPKD Patients
In: PR Newswire US, 2013-10-29
Online
Zeitungsartikel
Zugriff:
SHENYANG, China, Oct. 29, 2013 /PRNewswire/ -- 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the acquisition of patents for DJ5, a novel non-TZD PPARgamma agonist with potential to retard progressive renal failure in patients with autosomal dominant polycystic kidney disease ("ADPKD'). 3SBio intends to seek approval from the CFDA to undertake phase one clinical trials in China. [ABSTRACT FROM PUBLISHER]
Titel: |
3SBio to Develop DJ5 for Progressive Renal Failure in ADPKD Patients
|
---|---|
Autor/in / Beteiligte Person: | Newswire, PR |
Zeitschrift: | PR Newswire US, 2013-10-29 |
Veröffentlichung: | 2013 |
Medientyp: | Zeitungsartikel |
Schlagwort: |
|
Sonstiges: |
|